By Gary Giger, Director of Operations, Cotiviti Retail

In part one of this retail pharmacy series, we discussed the perfect storm facing pharmacy procurement teams. In this installment, we’re looking at the financial ramifications that continuing drug shortages can have on pharmacies.

Pharmacies feel shortage pain, too

Most discussions about drug shortages focus on patient care.

While patient access is certainly the top priority, there is another side of the equation that receives less attention: the financial impact on pharmacies. When a contracted manufacturer cannot supply product, pharmacies often have no choice but to purchase therapeutically equivalent alternatives from different suppliers. These replacement products frequently come at significantly higher costs.

According to the HHS Assistant Secretary for Planning and Evaluation (ASPE), the price of drugs in shortage increased 16.6%. In some cases, the price increase for substitute drugs was at least three times higher than the increase for the drug in shortage.

The challenge becomes even greater when the disruption impacts a manufacturer with a large market share. Industry experience has shown that remaining suppliers often cannot immediately absorb the additional demand. Prices increase, available inventory tightens, and pharmacies are forced into reactive purchasing decisions. This is why failure-to-supply (FTS) provisions have become increasingly important.

Missed recovery opportunities

Many manufacturers include provisions that compensate retailers when supply commitments are not met. However, identifying and collecting those recoveries is not always straightforward.

Over the years, I have seen organizations discover they were missing significant recovery opportunities simply because internal processes did not correctly identify qualifying events. In several instances, process reviews revealed that valid claims were never submitted despite clear supply disruptions.

According to DrugPatentWatch, most pharmaceutical supply agreements include a failure-to-supply clause that reimburses the buyer's incremental costs when a supplier cannot deliver, typically after a 30–60 day cure period. Yet this protection often goes uncaptured because procurement teams do not track supply failures closely enough to support a claim.

Shortages create operational challenges, poor visibility into shortages creates financial challenges, and the difference between the two often comes down to data, processes, and contract management. Supply disruption should be treated as both a clinical issue and a financial risk that requires active management.

Questions to ask

Critical assessment is prerequisite to tackling these challenges with clarity and specificity. Pharmacy buyers should be able to form strategic answers to questions like:

  • How is your organization balancing patient access priorities with the growing financial impact of supply disruptions?
  • Are pharmacy organizations doing enough to measure the true financial cost of drug shortages beyond the impact on product availability?
  • What strategies have been most effective in helping your organization manage supply disruption risk?

Final thoughts

Margin you don't track is margin you can't recover. Shortages will keep testing procurement teams, but the financial damage doesn't have to be permanent. When pharmacy teams and audit partners work together—combining operational knowledge with data and recovery experience—supply disruptions become events you can measure and claim instead of losses you absorb.

In part three, we turn to a related leak: contracts that are negotiated well but executed poorly.

About the author

GaryGiger_200x200

 

Gary Giger is Audit Director at Cotiviti, where he leads the Retail Pharmacy Group, delivering analysis and advisory services to chain retail pharmacies across the United States. With over 30 years of management experience spanning international and domestic post-audit engagements across industries in the US, Europe, Australia, and Asia, Gary brings a rare vantage point grounded in deep transactional data and real-world client outcomes.